



# Pneumonia Therapeutics Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-20	115	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

## Description

The global Pneumonia Therapeutics market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Pneumonia Therapeutics market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pneumonia Therapeutics market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

Asia Pacific: the Pneumonia Therapeutics market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pneumonia Therapeutics include Novartis, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Tetrphase Pharmaceuticals, Merck Sharp & Dohme and Biotest, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

## Report Scope

This report quantifies the global Pneumonia Therapeutics market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pneumonia Therapeutics.

## Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pneumonia Therapeutics Market by Company

Novartis

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Tetraphase Pharmaceuticals

Merck Sharp & Dohme

Biotest

### **Pneumonia Therapeutics Segment by Type**

Vaccines

Anti-Infectives

Oxygen Therapy

### **Pneumonia Therapeutics Segment by Application**

Clinic

Hospital

Medical Center

Other

### **Pneumonia Therapeutics Segment by Region**

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

### **Key Drivers & Barriers**

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## **Reasons to Buy This Report**

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## **Chapter Outline**

### **Chapter 1:**

Research objectives, research methods, data sources, data cross-validation;

### **Chapter 2:**

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

### **Chapter 3:**

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

### **Chapter 4:**

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

### **Chapter 5:**

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

### **Chapter 6:**

Detailed analysis of Pneumonia Therapeutics companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

**Chapter 12:**

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

**Chapter 13:**

The main points and conclusions of the report.

# Table of Contents

---

## 1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

---

## 2 Market Overview

- 2.1 Product Definition
- 2.2 Pneumonia Therapeutics by Type
  - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  - 2.2.2 Vaccines
  - 2.2.3 Anti-Infectives
  - 2.2.4 Oxygen Therapy
- 2.3 Pneumonia Therapeutics by Application
  - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  - 2.3.2 Clinic
  - 2.3.3 Hospital
  - 2.3.4 Medical Center
  - 2.3.5 Other
- 2.4 Assumptions and Limitations

---

## 3 Pneumonia Therapeutics Breakdown Data by Type

- 3.1 Global Pneumonia Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Pneumonia Therapeutics Forecasted Market Size by Type (2027-2032)

---

## 4 Pneumonia Therapeutics Breakdown Data by Application

- 4.1 Global Pneumonia Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Pneumonia Therapeutics Forecasted Market Size by Application (2027-2032)

---

## 5 Global Growth Trends

- 5.1 Global Pneumonia Therapeutics Market Perspective (2021-2032)
- 5.2 Global Pneumonia Therapeutics Growth Trends by Region
  - 5.2.1 Global Pneumonia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  - 5.2.2 Pneumonia Therapeutics Historic Market Size by Region (2021-2026)
  - 5.2.3 Pneumonia Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Pneumonia Therapeutics Market Dynamics
  - 5.3.1 Pneumonia Therapeutics Industry Trends
  - 5.3.2 Pneumonia Therapeutics Market Drivers
  - 5.3.3 Pneumonia Therapeutics Market Challenges
  - 5.3.4 Pneumonia Therapeutics Market Restraints

---

## 6 Market Competitive Landscape by Players

- 6.1 Global Top Pneumonia Therapeutics Players by Revenue

6.1.1 Global Top Pneumonia Therapeutics Players by Revenue (2021-2026)

6.1.2 Global Pneumonia Therapeutics Revenue Market Share by Players (2021-2026)

6.2 Global Pneumonia Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Pneumonia Therapeutics Head Office and Area Served

6.4 Global Pneumonia Therapeutics Players, Product Type & Application

6.5 Global Pneumonia Therapeutics Manufacturers Established Date

6.6 Global Pneumonia Therapeutics Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

---

## 7 North America

7.1 North America Pneumonia Therapeutics Market Size (2021-2032)

7.2 North America Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Pneumonia Therapeutics Market Size by Country (2021-2026)

7.4 North America Pneumonia Therapeutics Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

---

## 8 Europe

8.1 Europe Pneumonia Therapeutics Market Size (2021-2032)

8.2 Europe Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Pneumonia Therapeutics Market Size by Country (2021-2026)

8.4 Europe Pneumonia Therapeutics Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

---

## 9 Asia-Pacific

9.1 Asia-Pacific Pneumonia Therapeutics Market Size (2021-2032)

9.2 Asia-Pacific Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Pneumonia Therapeutics Market Size by Country (2021-2026)

9.4 Asia-Pacific Pneumonia Therapeutics Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

---

## 10 South America

10.1 South America Pneumonia Therapeutics Market Size (2021-2032)

10.2 South America Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America Pneumonia Therapeutics Market Size by Country (2021-2026)

10.4 South America Pneumonia Therapeutics Market Size by Country (2027-2032)

- 10.5 Brazil
  - 10.6 Argentina
  - 10.7 Chile
  - 10.8 Colombia
  - 10.9 Peru
- 

## 11 Middle East & Africa

- 11.1 Middle East & Africa Pneumonia Therapeutics Market Size (2021-2032)
  - 11.2 Middle East & Africa Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
  - 11.3 Middle East & Africa Pneumonia Therapeutics Market Size by Country (2021-2026)
  - 11.4 Middle East & Africa Pneumonia Therapeutics Market Size by Country (2027-2032)
  - 11.5 Saudi Arabia
  - 11.6 Israel
  - 11.7 United Arab Emirates
  - 11.8 Turkey
  - 11.9 Iran
  - 11.10 Egypt
- 

## 12 Players Profiled

- 12.1 Novartis
  - 12.1.1 Novartis Company Information
  - 12.1.2 Novartis Business Overview
  - 12.1.3 Novartis Revenue in Pneumonia Therapeutics Business (2021-2026)
  - 12.1.4 Novartis Pneumonia Therapeutics Product Portfolio
  - 12.1.5 Novartis Recent Developments
- 12.2 Pfizer
  - 12.2.1 Pfizer Company Information
  - 12.2.2 Pfizer Business Overview
  - 12.2.3 Pfizer Revenue in Pneumonia Therapeutics Business (2021-2026)
  - 12.2.4 Pfizer Pneumonia Therapeutics Product Portfolio
  - 12.2.5 Pfizer Recent Developments
- 12.3 GlaxoSmithKline
  - 12.3.1 GlaxoSmithKline Company Information
  - 12.3.2 GlaxoSmithKline Business Overview
  - 12.3.3 GlaxoSmithKline Revenue in Pneumonia Therapeutics Business (2021-2026)
  - 12.3.4 GlaxoSmithKline Pneumonia Therapeutics Product Portfolio
  - 12.3.5 GlaxoSmithKline Recent Developments
- 12.4 Bayer
  - 12.4.1 Bayer Company Information
  - 12.4.2 Bayer Business Overview
  - 12.4.3 Bayer Revenue in Pneumonia Therapeutics Business (2021-2026)
  - 12.4.4 Bayer Pneumonia Therapeutics Product Portfolio
  - 12.4.5 Bayer Recent Developments
- 12.5 AstraZeneca
  - 12.5.1 AstraZeneca Company Information
  - 12.5.2 AstraZeneca Business Overview
  - 12.5.3 AstraZeneca Revenue in Pneumonia Therapeutics Business (2021-2026)
  - 12.5.4 AstraZeneca Pneumonia Therapeutics Product Portfolio
  - 12.5.5 AstraZeneca Recent Developments
- 12.6 Tetrphase Pharmaceuticals

12.6.1 Tetrphase Pharmaceuticals Company Information

12.6.2 Tetrphase Pharmaceuticals Business Overview

12.6.3 Tetrphase Pharmaceuticals Revenue in Pneumonia Therapeutics Business (2021-2026)

12.6.4 Tetrphase Pharmaceuticals Pneumonia Therapeutics Product Portfolio

12.6.5 Tetrphase Pharmaceuticals Recent Developments

12.7 Merck Sharp & Dohme

12.7.1 Merck Sharp & Dohme Company Information

12.7.2 Merck Sharp & Dohme Business Overview

12.7.3 Merck Sharp & Dohme Revenue in Pneumonia Therapeutics Business (2021-2026)

12.7.4 Merck Sharp & Dohme Pneumonia Therapeutics Product Portfolio

12.7.5 Merck Sharp & Dohme Recent Developments

12.8 Biotest

12.8.1 Biotest Company Information

12.8.2 Biotest Business Overview

12.8.3 Biotest Revenue in Pneumonia Therapeutics Business (2021-2026)

12.8.4 Biotest Pneumonia Therapeutics Product Portfolio

12.8.5 Biotest Recent Developments

---

## **13 Report Conclusion**

---

## **14 Disclaimer**

# List of Tables and Figures

---

## List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Pneumonia Therapeutics Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Pneumonia Therapeutics Revenue Market Share by Type (2021-2026)
- Table 7: Global Pneumonia Therapeutics Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Pneumonia Therapeutics Revenue Market Share by Type (2027-2032)
- Table 9: Global Pneumonia Therapeutics Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Pneumonia Therapeutics Revenue Market Share by Application (2021-2026)
- Table 11: Global Pneumonia Therapeutics Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Pneumonia Therapeutics Revenue Market Share by Application (2027-2032)
- Table 13: Global Pneumonia Therapeutics Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Pneumonia Therapeutics Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Pneumonia Therapeutics Market Share by Region (2021-2026)
- Table 16: Global Pneumonia Therapeutics Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Pneumonia Therapeutics Market Share by Region (2027-2032)
- Table 18: Pneumonia Therapeutics Industry Trends
- Table 19: Pneumonia Therapeutics Industry Drivers
- Table 20: Pneumonia Therapeutics Industry Opportunities and Challenges
- Table 21: Pneumonia Therapeutics Market Restraints
- Table 22: Global Top Pneumonia Therapeutics Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Pneumonia Therapeutics Revenue Market Share by Players (2021-2026)
- Table 24: Global Pneumonia Therapeutics Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Pneumonia Therapeutics, Headquarters and Area Served
- Table 26: Global Pneumonia Therapeutics Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Pneumonia Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Pneumonia Therapeutics Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Pneumonia Therapeutics Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Pneumonia Therapeutics Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Pneumonia Therapeutics Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Pneumonia Therapeutics Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Pneumonia Therapeutics Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Pneumonia Therapeutics Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Pneumonia Therapeutics Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Pneumonia Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Pneumonia Therapeutics Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Pneumonia Therapeutics Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Novartis Company Information
- Table 46: Novartis Business Overview
- Table 47: Novartis Revenue in Pneumonia Therapeutics Business (2021-2026) & (US\$ Million)
- Table 48: Novartis Pneumonia Therapeutics Product Portfolio
- Table 49: Novartis Recent Developments
- Table 50: Pfizer Company Information
- Table 51: Pfizer Business Overview
- Table 52: Pfizer Revenue in Pneumonia Therapeutics Business (2021-2026) & (US\$ Million)
- Table 53: Pfizer Pneumonia Therapeutics Product Portfolio
- Table 54: Pfizer Recent Developments

- Table 55: GlaxoSmithKline Company Information
- Table 56: GlaxoSmithKline Business Overview
- Table 57: GlaxoSmithKline Revenue in Pneumonia Therapeutics Business (2021-2026) & (US\$ Million)
- Table 58: GlaxoSmithKline Pneumonia Therapeutics Product Portfolio
- Table 59: GlaxoSmithKline Recent Developments
- Table 60: Bayer Company Information
- Table 61: Bayer Business Overview
- Table 62: Bayer Revenue in Pneumonia Therapeutics Business (2021-2026) & (US\$ Million)
- Table 63: Bayer Pneumonia Therapeutics Product Portfolio
- Table 64: Bayer Recent Developments
- Table 65: AstraZeneca Company Information
- Table 66: AstraZeneca Business Overview
- Table 67: AstraZeneca Revenue in Pneumonia Therapeutics Business (2021-2026) & (US\$ Million)
- Table 68: AstraZeneca Pneumonia Therapeutics Product Portfolio
- Table 69: AstraZeneca Recent Developments
- Table 70: Tetrphase Pharmaceuticals Company Information
- Table 71: Tetrphase Pharmaceuticals Business Overview
- Table 72: Tetrphase Pharmaceuticals Revenue in Pneumonia Therapeutics Business (2021-2026) & (US\$ Million)
- Table 73: Tetrphase Pharmaceuticals Pneumonia Therapeutics Product Portfolio
- Table 74: Tetrphase Pharmaceuticals Recent Developments
- Table 75: Merck Sharp & Dohme Company Information
- Table 76: Merck Sharp & Dohme Business Overview
- Table 77: Merck Sharp & Dohme Revenue in Pneumonia Therapeutics Business (2021-2026) & (US\$ Million)
- Table 78: Merck Sharp & Dohme Pneumonia Therapeutics Product Portfolio
- Table 79: Merck Sharp & Dohme Recent Developments
- Table 80: Biotest Company Information
- Table 81: Biotest Business Overview
- Table 82: Biotest Revenue in Pneumonia Therapeutics Business (2021-2026) & (US\$ Million)
- Table 83: Biotest Pneumonia Therapeutics Product Portfolio
- Table 84: Biotest Recent Developments
- Table 85: Authors List of This Report

### List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Pneumonia Therapeutics Product Image
- Figure 5: Global Pneumonia Therapeutics Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Pneumonia Therapeutics Market Share by Type: 2025 VS 2032
- Figure 7: Vaccines Product
- Figure 8: Anti-Infectives Product
- Figure 9: Oxygen Therapy Product
- Figure 10: Global Pneumonia Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 11: Global Pneumonia Therapeutics Market Share by Application: 2025 VS 2032
- Figure 12: Clinic Product
- Figure 13: Hospital Product
- Figure 14: Medical Center Product
- Figure 15: Other Product
- Figure 16: Global Pneumonia Therapeutics Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 17: Global Pneumonia Therapeutics Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 18: Global Pneumonia Therapeutics Market Share by Region: 2025 VS 2032
- Figure 19: Global Pneumonia Therapeutics Market Share by Players in 2025
- Figure 20: Global Pneumonia Therapeutics Manufacturers Established Date
- Figure 21: Global Top 5 and 10 Pneumonia Therapeutics Players Market Share by Revenue in 2025
- Figure 22: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 23: North America Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 24: North America Pneumonia Therapeutics Market Share by Country (2021-2032)
- Figure 25: United States Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: Canada Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 27: Mexico Pneumonia Therapeutics Market Share by Country (2021-2032)
- Figure 28: Europe Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: Europe Pneumonia Therapeutics Market Share by Country (2021-2032)
- Figure 30: Germany Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)

- Figure 31: France Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: U.K. Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: Italy Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Spain Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Russia Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Netherlands Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Nordic Countries Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Asia-Pacific Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Asia-Pacific Pneumonia Therapeutics Market Share by Country (2021-2032)
- Figure 40: China Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Japan Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: South Korea Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: India Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: India Pneumonia Therapeutics Market Share by Country (2021-2032)
- Figure 45: Australia Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: China Taiwan Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: Southeast Asia Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: South America Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: South America Pneumonia Therapeutics Market Share by Country (2021-2032)
- Figure 50: Brazil Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: Argentina Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Chile Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Colombia Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Peru Pneumonia Therapeutics Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 55: Novartis Revenue Growth Rate in Pneumonia Therapeutics Business (2021-2026)
- Figure 56: Pfizer Revenue Growth Rate in Pneumonia Therapeutics Business (2021-2026)
- Figure 57: GlaxoSmithKline Revenue Growth Rate in Pneumonia Therapeutics Business (2021-2026)
- Figure 58: Bayer Revenue Growth Rate in Pneumonia Therapeutics Business (2021-2026)
- Figure 59: AstraZeneca Revenue Growth Rate in Pneumonia Therapeutics Business (2021-2026)
- Figure 60: Tetrphase Pharmaceuticals Revenue Growth Rate in Pneumonia Therapeutics Business (2021-2026)
- Figure 61: Merck Sharp & Dohme Revenue Growth Rate in Pneumonia Therapeutics Business (2021-2026)
- Figure 62: Biotest Revenue Growth Rate in Pneumonia Therapeutics Business (2021-2026)